SYRE – spyre therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Wall Street
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]
Form 4 Spyre Therapeutics, Inc. For: Dec 01 Filed by: Turtle Cameron
Form 4 Spyre Therapeutics, Inc. For: Nov 03 Filed by: Turtle Cameron
Form 8-K Spyre Therapeutics, Inc. For: Nov 04
Form 10-Q Spyre Therapeutics, Inc. For: Sep 30
Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.